Table 2.
Demographics table
| Overall population N = 157 439 | |||||
|---|---|---|---|---|---|
| Age | Mean | Std | |||
| 66.04 | 7.27 | ||||
| Age categories | N | % | Use of antidiabetic medications | N | % |
| 55-59 | 37 940 | 24.1% | All classes | 125 802 | 79.9% |
| 60-64 | 31 902 | 20.3% | Metformin | 95 342 | 60.6% |
| 65-69 | 35 062 | 22.3% | Insulin | 37 587 | 23.9% |
| 70-74 | 22 781 | 14.5% | TZD | 27 860 | 17.7% |
| 75-79 | 25 695 | 16.3% | Sulfonylureas | 59 542 | 37.8% |
| ≥ 80 | 4059 | 2.6% | DPP-4 inhibitors | 22 504 | 14.3% |
| Sex | N | % | GLP-1 receptor agonists | 6740 | 4.3% |
| Male | 78 530 | 49.9% | α-blockers | 882 | 0.6% |
| Female | 78 909 | 50.1% | Meglitinides | 2870 | 1.8% |
| Race | N | % | Use of other medications | N | % |
| Asian | 8195 | 5.2% | Bisphosphonates | 9122 | 5.8% |
| Black | 25 647 | 16.3% | Raloxifene | 1431 | 0.9% |
| White | 99 056 | 62.9% | Estrogens | 6797 | 4.3% |
| Hispanic | 14 888 | 9.5% | Glucocorticoids | 32 844 | 20.6% |
| Other/Unknown | 9653 | 6.1% | Comorbidities | N | % |
| HbA1c bins | N | % | Neuropathy | 40 062 | 25.4% |
| 6%-7% | 86 211 | 54.8% | Retinopathy | 30 006 | 19.1% |
| 7%-8% | 40 204 | 25.5% | Nephropathy | 40 371 | 25.6% |
| 8%-9% | 16 185 | 10.3% | Coronary artery disease | 47 443 | 30.1% |
| 9%-10% | 7525 | 4.8% | Stroke | 30 072 | 19.1% |
| 10%-11% | 3752 | 2.4% | Hypertension | 146 113 | 92.8% |
| 11%-12% | 1933 | 1.2% | Obesity | 35 442 | 22.5% |
| ≥ 12% | 1629 | 1.0% | Osteoporosis | 16 756 | 10.6% |
| T2D history | N | % | Previous fragility fractures (observational period) | N | % |
| Prevalent T2D | 42 807 | 27.2% | |||
| Incident T2D | 114 632 | 72.8% | Previous fractures | 4965 | 3.2% |
Please note the relatively low obesity percentage is due to limited availability of body mass index data through claims database.
Abbreviations: HbA1c, glycated hemoglobin; T2D, type 2 diabetes.